34 news items
Page 2 of 2
6wb6cndxn05fmy
ABBV
BMY
17 May 24
dosing frequency (QD vs. BD), better GI safety profile, and potentially greater efficacy (PANSS score),” Cantor writes.
The analyst says
8yhg599c51aejo
ABBV
17 May 24
presentations include efficacy and safety data evaluating clinical, endoscopic, and histologic outcomes from both the INSPIRE Phase 3 induction study
3qlg84cwzlsgu nsw
ABBV
17 May 24
include efficacy and safety data evaluating clinical, endoscopic, and histologic outcomes from both the INSPIRE Phase 3
yct0c0f3g4xb7whhknj ftw0pwufyjpye1vv5y
ABBV
13 May 24
are optimized for safety, efficacy, and patient access. Gilgamesh is advancing a diverse portfolio of programs, including two lead clinical programs
tbzlljwv114azn41d7qh7vw6z4lcujkb6bte9ffe4lli0twtnfw41z64fl1
ABBV
25 Apr 24
or when use of those therapies was inadvisable1The safety profile of upadacitinib was consistent with the profile in previous atopic
pcpz pst89klxa6mz
ABBV
25 Apr 24
The safety profile of upadacitinib was consistent with the profile in previous atopic dermatitis studies with no new safety signals
bnrluov1z8m8z2fhrix
ABBV
CERE
18 Apr 24
disease.
The TEMPO-3 trial evaluated the efficacy, safety, and tolerability of tavapadon as an adjunctive
316r7pys860z2dk0w7sda9pd7t4yj4t60
ABBV
18 Apr 24
to 29 percent of patients receiving placebo with a 52-week steroid taper regimen1− The safety profile in GCA
gjbateysrqvp1r5x8r172 b1s9
ABBV
18 Apr 24
− The safety profile in GCA was generally consistent with that in approved indications, and no new safety signals were
5mbwy75fvydgk rduotx0skta094yji61s4drqnmy46webbo
ABBV
12 Apr 24
an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant
lqv2aoyx4g4oro225nudnid38t
ABBV
12 Apr 24
, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine
3merxiu63s
ABBV
12 Apr 24
extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic
t16pzdhwq4zgxzxshzyai1fxtrg0q4sfyo6
ABBV
LENZ
10 Apr 24
.
In contrast, LNZ100 has demonstrated clinically significant all-day near-vision improvement (~10 hours) with no notable safety issues
l1pcqsfcumevei4xs5cls3fmo34vfyn2im87aorygfpwcn0m1njxyu9chu7b
ABBV
3 Apr 24
and Important Safety Information for CoolSculpting® and CoolSculpting® Elite